The primary aim of the PRO-ACTIVE study is to compare the effectiveness of PRO-ACTIVE versus RE-ACTIVE swallowing interventions among patients with head and neck cancer who are scheduled to undergo radiotherapy. Our study hypothesis is that PRO-ACTIVE therapies are more effective than RE-ACTIVE therapy, and that more intensive PRO-ACTIVE (EAT + EXERCISE) therapy is superior to less intensive PRO-ACTIVE (EAT) therapy. Therapeutic effectiveness will be measured at 3-months following radiotherapy and will be based on reduced feeding tube dependency.
This multi-site trial is currently taking place at seven hospitals in Canada and the United States, with four more sites to be added soon. Enrollment will conclude in January 2022.
PRO-ACTIVE was featured in a short video by The Princess Margaret Cancer Foundation.
For more information, please visit the Patient-Centered Outcomes Research Institute.
For detailed study information on ClinicalTrials.gov please click here.